Clearside Biomedical

Clearside Biomedical Liabilities

Delisted

The The Liabilities of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 63.98 M USD. In the previous year, The Liabilities was 49.93 M USD — a change of 28.14% (higher).

Liabilities

63.98 MUSD

YoY

28.14%

Last updated:

In 2024, Clearside Biomedical's total liabilities amounted to 63.98 M USD, a 28.14% difference from the 49.93 M USD total liabilities in the previous year.

The Clearside Biomedical Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
19.08 M USD
Jan 1, 2018
20.50 M USD
Jan 1, 2019
15.62 M USD
Jan 1, 2020
10.56 M USD
Jan 1, 2021
4.93 M USD
Jan 1, 2022
40.70 M USD
Jan 1, 2023
49.93 M USD
Jan 1, 2024
63.98 M USD
The Clearside Biomedical Liabilities history
YEARLiabilitiesYoY
63.98 MUSD+28.14%
49.93 MUSD+22.68%
40.70 MUSD+725.56%
4.93 MUSD-53.31%
10.56 MUSD-32.39%
15.62 MUSD-23.80%
20.50 MUSD+7.44%
19.08 MUSD+45.10%
13.15 MUSD+26.44%
10.40 MUSD+288.06%
2.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Clearside Biomedical's Liabilities

Clearside Biomedical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Clearside Biomedical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Clearside Biomedical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Clearside Biomedical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Clearside Biomedical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Clearside Biomedical stock

The Liabilities of Clearside Biomedical is 63.98 M USD in 2024.

The Liabilities of Clearside Biomedical changed from 49.93 M USD to 63.98 M USD, representing a 28.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical